Literature DB >> 15800997

Liver fibrosis caused by choledocholith to regress after biliary drainage.

Zuo-Bing Chen1, Shu-Sen Zheng, Guo-Zhi Hu, Yuan Gao, Chen-Yan Ding, Yun Zhang, Xue-Hong Zhao, Lin-Mei Ni.   

Abstract

AIM: To study the correlation between liver fibrosis severity and biliary drainage in patients with choledocholith.
METHODS: A follow-up study on seven patients with liver fibrosis due to choledocholith was made. The data, including biochemical tests (aspartate aminotransferase, alanine aminotransferase) and liver histological features before and after biliary drainage, were collected and studied. The fibrosis severity was scored on a scale from 0 to 3, with 0 denoting none, 1 portal and periportal fibrosis, 2 the presence of numerous fiber septa, and 3 cirrhosis. The average liver fibrosis severity scores of the first and second biopsy were compared with statistical method.
RESULTS: The first, second liver fibrosis severity scores of these seven patients were 2,1; 2,1; 1,0; 1,1; 2,1; 2,1; 1,0 respectively. The results showed that the average liver fibrosis severity score of the second liver biopsy decreased significantly compared with the first liver biopsy (n = 7, t = 4.25, P<0.05).
CONCLUSION: Liver fibrosis due to choledocholith may regress after biliary drainage.

Entities:  

Mesh:

Year:  2005        PMID: 15800997      PMCID: PMC4305728          DOI: 10.3748/wjg.v11.i13.2013

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  12 in total

1.  [Reconstruction of bile duct lesions by an autologous vein graft and a bio-degradable endoluminal stent in an animal model: technique and clinical impact].

Authors:  H P Heistermann; D Palmes; H Hierlemann; M Ebsen; R Horstmann; G Hohlbach; H U Spiegel
Journal:  Zentralbl Chir       Date:  2003-11       Impact factor: 0.942

2.  High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity.

Authors:  M F Donato; E Arosio; E Del Ninno; G Ronchi; P Lampertico; A Morabito; M R Balestrieri; M Colombo
Journal:  Hepatology       Date:  2001-09       Impact factor: 17.425

Review 3.  Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal.

Authors:  Ramón Bataller; Kari E North; David A Brenner
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

4.  Fibrillin-1 expression in normal and fibrotic rat liver and in cultured hepatic fibroblastic cells: modulation by mechanical stress and role in cell adhesion.

Authors:  Dionne Lorena; Ian A Darby; Dieter P Reinhardt; Vincent Sapin; Jean Rosenbaum; Alexis Desmoulière
Journal:  Lab Invest       Date:  2004-02       Impact factor: 5.662

5.  Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?

Authors:  G P Aithal; B Haugk; S Das; T Card; A D Burt; C O Record
Journal:  Aliment Pharmacol Ther       Date:  2004-02-15       Impact factor: 8.171

6.  P-selectin suppresses hepatic inflammation and fibrosis in mice by regulating interferon gamma and the IL-13 decoy receptor.

Authors:  Thomas A Wynn; Matthias Hesse; Netanya G Sandler; Mallika Kaviratne; Karl F Hoffmann; Monica G Chiaramonte; Rachael Reiman; Allen W Cheever; Joseph P Sypek; Margaret M Mentink-Kane
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

7.  Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress.

Authors:  Gaetano Serviddio; Javier Pereda; Federico V Pallardó; Julian Carretero; Consuelo Borras; Juan Cutrin; Gianluigi Vendemiale; Giuseppe Poli; José Viña; Juan Sastre
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

8.  Effects of silymarin and vitamins E and C on liver damage induced by prolonged biliary obstruction in the rat.

Authors:  Pablo Muriel; Mario G Moreno
Journal:  Basic Clin Pharmacol Toxicol       Date:  2004-02       Impact factor: 4.080

9.  The effect of taurine treatment on oxidative stress in experimental liver fibrosis.

Authors:  Mehmet Refik Mas; Bilgin Comert; Kemal Oncu; Sevil Atalay Vural; Cemal Akay; Ilker Tasci; Esber Ozkomur; Muhittin Serdar; Nuket Mas; Gülay Alcigir; Nuran Yener
Journal:  Hepatol Res       Date:  2004-04       Impact factor: 4.288

10.  Is there a difference in diagnostic accuracy and clinical impact between endoscopic ultrasonography and magnetic resonance cholangiopancreatography?

Authors:  A P Ainsworth; S R Rafaelsen; P A Wamberg; J Durup; T K Pless; M B Mortensen
Journal:  Endoscopy       Date:  2003-12       Impact factor: 10.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.